Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular DystrophyGlobeNewsWire • 07/11/25
Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne PatientsBenzinga • 06/20/25
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular DystrophyGlobeNewsWire • 06/20/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRGlobeNewsWire • 06/18/25
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy ProgramGlobeNewsWire • 06/17/25
Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel AdvancementSeeking Alpha • 06/11/25
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy ProgramGlobeNewsWire • 06/11/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. - CAPRGlobeNewsWire • 06/06/25
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the InvestigationAccesswire • 06/03/25
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities InvestigationAccesswire • 06/02/25
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to ConnectAccesswire • 06/01/25
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach OutAccesswire • 05/30/25
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities InvestigationAccesswire • 05/29/25
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Investors to Learn More About the InvestigationAccesswire • 05/28/25
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationAccesswire • 05/27/25
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to ConnectAccesswire • 05/26/25
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Investors to Inquire about Securities InvestigationAccesswire • 05/23/25
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Reach OutAccesswire • 05/22/25
Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA DecisionSeeking Alpha • 05/22/25
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Reach OutAccesswire • 05/21/25